Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case

Huang, Tsung-Yi; Lin, Jih-Pin; Lieu, Ann-Shung; Chen, Yi-Ting; Chen, Hung-Sheng; Jang, Mei-Yu; Shen, Jung-Tsung; Wu, Wen‐Jeng; Huang, Shu‐Pin; Juan, Yung‐Shun

doi:10.1186/1477-7819-11-254

Cited by 17 publications

(19 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Case reports have described the occurrence of granulomas at the injection site with GnRH agonist injections , which may be due to the GnRH analogue itself or to another constituent of the formulation . Pituitary apoplexy , interstitial pneumonitis , and anaphylaxis have also all been reported after GnRH agonist administration. These AEs seem to have a low incidence and it remains to be established whether they are connected to a specific agent or represent a class effect of GnRH agonist therapy.…”

Section: Discussionmentioning

confidence: 99%

Are all gonadotrophin‐releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review

Bolton

Lynch

2018

BJU International

View full text Add to dashboard Cite

To review direct comparative studies of the gonadotrophin-releasing hormone (GnRH) agonists goserelin, triptorelin, and leuprorelin for the treatment of prostate cancer, and identify whether there are meaningful clinical differences between these agents. In June 2017, the following searches were performed independently by two reviewers in PubMed: (i) 'prostate cancer' and 'triptorelin' and 'leuprorelin', (ii) 'prostate cancer' and 'triptorelin' and 'goserelin', and (iii) 'prostate cancer' and 'goserelin' and 'leuprorelin', without time restriction. Duplicates were deleted. Relevant conference abstracts were also screened. A total of 16 direct comparative trials were identified: 12 reported on efficacy outcomes, four on safety/tolerability, and five on the convenience of administration/user perceptions. These studies are restricted in terms of patient numbers, formulations assessed, and endpoints measured; none were adequately powered for survival outcome measures. Studies reporting on efficacy endpoints did not show major differences in the ability of these GnRH agonists to reduce levels of testosterone or prostate-specific antigen. Some studies suggest differences in short- or long-term testosterone control, the rate of injection site adverse events, and patient/healthcare professional perceptions, but definitive conclusions cannot be drawn from the existing evidence. Few direct comparative trials of GnRH agonists have been conducted. Whilst GnRH agonists provide a similar castration effect, there is not enough evidence to show that GnRH agonists are equivalent.

show abstract

Section: Discussionmentioning

confidence: 99%

Are all gonadotrophin‐releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review

Bolton

Lynch

2018

BJU International

View full text Add to dashboard Cite

show abstract

“…Hormonal gonadotropinomas. 145,146 Symptoms commonly occur on the first day after the first dose, with rare presentations occurring as late as the ninth or tenth day following injection. 145 Patients receiving these agents should be instructed and carefully monitored regarding symptoms of pituitary apoplexy and promptly undergo evaluation in cases of any suspicion.…”

Section: Hormonal Therapiesmentioning

confidence: 99%

Anticancer Medications and Sodium Dysmetabolism

Bhattacharya

Lathia

Kantroo

et al. 2020

European Endocrinology

View full text Add to dashboard Cite

“…Increased estrogen states, such as exogenous estrogen administration, pregnancy, and postpartum period, have been reported to cause PA [33,[36][37][38]. Treatment with GnRH agonists for prostate cancer has also been associated with PA [39][40][41].…”

Section: Imbalance Between the Stimulation Of The Pituitary And The Amentioning

confidence: 99%

“…The role of dopamine agonist (DAs) treatment as precipitating factor is more controversial, although many case reports suggested this hypothesis [42,43]. In prospective studies analyzing the effects of DAs on macroprolactinomas, PA were very rarely or never observed [6,[44][45][46].…”

Section: Imbalance Between the Stimulation Of The Pituitary And The Amentioning

confidence: 99%

Pituitary Apoplexy

Jemel¹,

Alaya²,

Boubaker³

et al. 2019

Pituitary Diseases

View full text Add to dashboard Cite

Pituitary apoplexy is a rare clinical emergency due to acute ischemic infarction or hemorrhage of the pituitary gland. As this disorder most often involves a pituitary adenoma, especially nonfunctioning tumors, the syndrome should be referred to as pituitary tumor apoplexy. The precise physiopathology is not completely clear. Although in most cases it occurs spontaneously, pituitary apoplexy can be precipitated by many risk factors. The main symptom is headache of sudden onset associated with visual disturbances, signs of meningeal irritation, and/or endocrine dysfunction. Corticotropic deficiency is a potentially life-threatening disorder. Magnetic resonance imaging is the most sensitive to confirm the diagnosis by revealing a pituitary tumor with hemorrhagic and/or necrotic components. Earlier studies used to consider urgent decompression of the lesion surgically, but nowadays, more recent studies favor conservative management in selected patients (those without important visual acuity or field defects and with normal consciousness). This wait-and-see approach gives evidence of excellent outcomes in terms of oculomotor palsy, pituitary function, and subsequent tumor growth. Surgical decompression may be necessary in some cases. Once the acute phase is over, the patient should be reevaluated for hormonal deficiencies. Moreover, spontaneous remission of syndromes, such as acromegaly, may be caused by pituitary adenoma apoplexy.

show abstract

Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case

Cited by 17 publications

References 12 publications

Are all gonadotrophin‐releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review

Are all gonadotrophin‐releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review

Anticancer Medications and Sodium Dysmetabolism

Pituitary Apoplexy

Contact Info

Product

Resources

About